Recommendations for analytical antiretroviral treatment interruptions in HIV research trials: report of a consensus meeting

Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research

Selective predation by Lestes (Odoiiata, Lestidae) on littoral microcrustacea

Two experimental approaches were used to examine the predation risk of six littoral cladoceran and ostracod species to two size classes of the damselfly Lestes sp. Behavioural observations were conducted in a 2–1 arena and predation rate experiments in 1–1 jars in the laboratory.  Behavioural observations revealed that attack and capture efficiencies by Lestes were higher on smaller cladocerans (Polyphemus and Ceriodaphnia) than on other taxa. Small Lestes had little success ingesting the small ostracod Cypridopsis, whereas larger Lestes captured and ate it easily.  Predation‐rate experiments showed that Lestes has a clear preference for smaller cladocerans over both a large cladoceran Simocephatus and all three ostracods (Cypricercus, Cyclocypris, and Cypridopsis). Most Lestes were unable to consume the larger Cypricercus.  Attack rates and predation rates were highly variable among individual predators.  These data indicate that damselfly larvae are size selective and consume all but very large cladocerans more readily than ostracods. Copyright © 1993, Wiley Blackwell. All rights reserve

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research